Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT04908722

A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults

COVID-19 Prevention Clinical Trial

Official title:
A Randomized, Double-blind, Phase 3 Study to Evaluate 6 Dose Levels of Ad26.COV2.S Administered As a Two-Dose Schedule in Healthy Adults

Clinical Trial Summary

The purpose of this study is to demonstrate non-inferiority (NI) in terms of humoral immune responses after 6 dose levels of Ad26.COV2.S.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04908722
Study type Interventional
Source Janssen Vaccines & Prevention B.V.
Contact
Status Completed
Phase Phase 3
Start date June 18, 2021
Completion date July 10, 2023
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04640233 - Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) Infection Phase 2/Phase 3
Completed NCT05091307 - A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults Phase 3
Completed NCT05122260 - PREVENT-COVID-19: A Q-Griffithsin Intranasal Spray Phase 1
Recruiting NCT04858633 - Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19 Phase 3
Recruiting NCT05437029 - Safety, Tolerability, and Pharmacokinetics of Q-Griffithsin Intranasal Spray Phase 1
Completed NCT04436276 - A Study of Ad26.COV2.S in Adults (COVID-19) Phase 1/Phase 2
Active, not recruiting NCT04713488 - An Open Study on the Safety, Tolerability, and Immunogenicity of "Sputnik Light" Vaccine Phase 1/Phase 2
Recruiting NCT04741061 - Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light Phase 3
Completed NCT04765384 - A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19) Phase 2